Personalized Blood Treatment System with Integrated AI, IoT, and Blockchain Technologies

The disclosed inventive concept integrates a blood treatment apparatus with AI, IoT, and blockchain technologies to create a personalized, real-time optimized, and secure blood treatment system.

The original patent, related to a method for setting a control device or a closed-loop control device of a blood treatment apparatus, had limitations in terms of real-time optimization, patient data management, and supply chain security. The new inventive concept addresses these limitations by integrating AI-driven treatment optimization, IoT-enabled sensor networks, and blockchain-based patient data management and supply chain management.

The inventive concept comprises a blood treatment apparatus, an AI-driven treatment optimization module, an IoT-enabled sensor network, and a blockchain-based patient data management system. The AI module dynamically adjusts treatment parameters based on real-time patient data and medical research updates. The IoT sensor network provides real-time monitoring of treatment parameters, which are analyzed by the AI analytics engine. The blockchain system ensures secure storage and sharing of patient health data, as well as authenticity and quality of dialysis liquid supplies.

The new claims introduce the synergistic combination of AI, IoT, and blockchain technologies with a blood treatment apparatus, enabling real-time optimization, secure patient data management, and supply chain security. This integration is non-obvious and novel compared to the original patent.

Alternative embodiments could include integrating the AI module with other medical devices, using different blockchain platforms, or incorporating additional IoT sensors. Variations could include adapting the system for different blood treatment modalities or incorporating additional features such as telemedicine or remote monitoring.

The inventive concept has significant commercial potential in the medical device and healthcare industries, particularly in the areas of personalized medicine, telemedicine, and supply chain management. The system could be marketed to hospitals, clinics, and dialysis centers, as well as to patients and caregivers seeking more effective and convenient blood treatment options.